Abstract
Strategies for prevention of venous thromboembolism in orthopaedic patients undergoing major lower limb surgery include pharmacological prophylaxis. Over the last three decades, the search for new safe and effective approaches for the prevention of venous thromboembolism in these patients has continued. Increased understanding of the haemostatic process has led to a clearer appreciation of the mechanisms of action of antithrombotic drugs already in use as well as the identification of new targets for novel drug development. As a result, the development of new anticoagulants has advanced rapidly over recent years. The molecular targets of several novel anticoagulants, and their effectiveness in early Phase II and Phase III trials are reviewed.
Keywords: Anticoagulants, venous thromboembolism, pulmonary embolism, haemostasis, thromboprophylaxis, antithrombotic drugs, prophylaxis, fibrinolytic mechanism, intravascular thrombosis, ticlopidine, vasoconstriction, Von Willebrand factor, serotonin, prostaglandins, factor X, antithrombin, auto-regulation, tissue factor pathway inhibitor (TFPI), Heparin, penta-saccharide, Thrombomodulin, tissue-type plasminogen, urokinase-type plasminogen activator (uPA), plasmin (via alpha2-antiplasmin), hemorhelogy, vascular bifurcations, atheromatous, Virchow's triad, sequelae, Varicose veins, pulmonary emboli, fatal pulmonary emboli, (hirudin), specific factor Xa inhibitors (fondaparinux), oral warfarin sodium, haematophagous organisms, Tifacogin, FVIIai, NAPc2, Fondaparinux, Idraparinux, DX9065a, LY 517717, Razaxaban, Rivaroxaban (BAY59-7939), SSR12517E, SSR123781A, Otamixaben, Apixaban, Ximelagatran, Dabigatran etexilate
Current Vascular Pharmacology
Title: The Plasma Coagulation Cascade: Potential Targets for Novel Anticoagulants in Major Lower Limb Surgery
Volume: 9 Issue: 1
Author(s): Elizabeth O. Johnson, Maria Konstandi, George C. Babis, Mara Piagkou and Panayotis N. Soucacos
Affiliation:
Keywords: Anticoagulants, venous thromboembolism, pulmonary embolism, haemostasis, thromboprophylaxis, antithrombotic drugs, prophylaxis, fibrinolytic mechanism, intravascular thrombosis, ticlopidine, vasoconstriction, Von Willebrand factor, serotonin, prostaglandins, factor X, antithrombin, auto-regulation, tissue factor pathway inhibitor (TFPI), Heparin, penta-saccharide, Thrombomodulin, tissue-type plasminogen, urokinase-type plasminogen activator (uPA), plasmin (via alpha2-antiplasmin), hemorhelogy, vascular bifurcations, atheromatous, Virchow's triad, sequelae, Varicose veins, pulmonary emboli, fatal pulmonary emboli, (hirudin), specific factor Xa inhibitors (fondaparinux), oral warfarin sodium, haematophagous organisms, Tifacogin, FVIIai, NAPc2, Fondaparinux, Idraparinux, DX9065a, LY 517717, Razaxaban, Rivaroxaban (BAY59-7939), SSR12517E, SSR123781A, Otamixaben, Apixaban, Ximelagatran, Dabigatran etexilate
Abstract: Strategies for prevention of venous thromboembolism in orthopaedic patients undergoing major lower limb surgery include pharmacological prophylaxis. Over the last three decades, the search for new safe and effective approaches for the prevention of venous thromboembolism in these patients has continued. Increased understanding of the haemostatic process has led to a clearer appreciation of the mechanisms of action of antithrombotic drugs already in use as well as the identification of new targets for novel drug development. As a result, the development of new anticoagulants has advanced rapidly over recent years. The molecular targets of several novel anticoagulants, and their effectiveness in early Phase II and Phase III trials are reviewed.
Export Options
About this article
Cite this article as:
O. Johnson Elizabeth, Konstandi Maria, C. Babis George, Piagkou Mara and N. Soucacos Panayotis, The Plasma Coagulation Cascade: Potential Targets for Novel Anticoagulants in Major Lower Limb Surgery, Current Vascular Pharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157016111793744779
DOI https://dx.doi.org/10.2174/157016111793744779 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Overview of Current Trends and the Future of Thromboprophylaxis in Orthopaedic Surgery
Vascular Disease Prevention (Discontinued) The Role of Electrospinning in the Emerging Field of Nanomedicine
Current Pharmaceutical Design Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design Alcoholic Liver Disease and Hepatitis C Chronic Infection
Reviews on Recent Clinical Trials Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Current Genomics Treatment of Disorders Characterized by Reversible Airway Obstruction in Childhood: are Anti-cholinergic Agents the Answer?
Current Pharmaceutical Design Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Pharmacological Agents in the Treatment of Venous Disease: An Update of the Available Evidence
Current Vascular Pharmacology Ambroxol Chaperone Therapy for Gaucher Disease Type I-Associated Liver Cirrhosis and Portal Hypertension: A Case Report
Endocrine, Metabolic & Immune Disorders - Drug Targets Endometriosis and Perinatal Outcome - A Systematic Review of the Literature
Current Women`s Health Reviews Semicarbazide-Sensitive Amine Oxidase: Current Status and Perspectives
Current Medicinal Chemistry Scientific Papers and Patents on Substances with Unproven Effects. Part 2
Recent Patents on Drug Delivery & Formulation Variations and Abnormalities of Major Thoracic Vascular Structures
Current Medical Imaging Plasmodium Drug Targets Outside the Genetic Control of the Parasite
Current Pharmaceutical Design P2X Receptors in the Cardiovascular System and their Potential as Therapeutic Targets in Disease
Current Medicinal Chemistry The Role of MDCT in Craniocervical Junction Pathologies: Pictorial Review
Current Medical Imaging Nummular Eczema: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery The Saphenous Vein as a Bypass Conduit: The Potential Role of Vascular Nerves in Graft Performance
Current Vascular Pharmacology Medical Treatment of Chronic Venous Insufficiency
Vascular Disease Prevention (Discontinued) Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets